Tacrolimus (FK506), an immunosuppressive agent, prevents indomethacin-induced small intestinal ulceration in the rat: Inhibition of inducible nitric oxide synthase expression

Journal of Pharmacological Sciences

Volumn 103, Issue 1, 2007, Pages 40-47

  Kato, Shinichi ^a   Nishio, Hikaru ^a   Ogura, Michitaka ^a   Takeuchi, Koji ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Indomethacin; Inducible nitric oxide synthase (iNOS); Nuclear factor (NF) B; Small intestinal ulceration; Tacrolimus (FK506)

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; INDOMETACIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; MYELOPEROXIDASE; TACROLIMUS; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; GEL MOBILITY SHIFT ASSAY; ILEUM; INTESTINE INJURY; INTESTINE ULCER; JEJUNUM; LIPID PEROXIDATION; MALE; NONHUMAN; PROTEIN DNA BINDING; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SMALL INTESTINE;

EID: 33846628145     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0061181     Document Type: Article

References (31)

1. Robert A, Asano T. Resistance of germ-free rats to indomethacin-induced intestinal inflammation. Prostaglandins. 1977;14:333-341.
2. Fang WF, Broughton A, Jacobson ED. Indomethacin induced intestinal inflammation. Am J Dig Dis. 1977;22:749-760.
3. Whittle BJR. Temporal relationship between cyclooxygenase inhibition as measured by prostacyclin biosynthasus and the gastrointestinal damage induced by indomethacin in rat. Gastroenterology. 1981;80:94-98.
4. Weissenborn U, Maedge S, Buettner D, Sewing KF. Indomethacin-increased gastrointestinal lesions in relation to tissue concentration, food intake and bacterial invasion in the rat. Pharmacology. 1985;30:32-39.
5. Yamada T, Deitch E, Specian RD, Perry MA, Sartor RB, Grisham MB. Mechanisms of acute and chronic intestinal inflammation induced by indomethacin. Inflammation. 1993;17:641-662.
6. Whittle BJR, Laszlo F, Evans SM, Moncada S. Induction of nitric oxide synthase and microvascular injury in the rat jejunum provoked by indomethacin. Br J Pharmacol. 1995;116:2286-2290.
7. Konaka A, Tanaka A, Kato S, Nishijima M, Takeuchi K. Nitric oxide, superoxide radicals and mast cells in pathogenesis of indomethacin-induced intestinal lesions in rats. J Pharmacol Physiol. 1999;50:25-38.
8. Tanaka A, Kunikata T, Mizoguchi H, Kato S, Takeuchi K. Dual action of nitric oxide in pathogenesis of indomethacin-induced small intestinal ulceration in rats. J Physiol Pharmacol. 1999;50:405-417.
9. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, et al. FK506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physicochemical and biological characteristics. J Antibiot (Tokyo). 1987;40:1249-1255.
10. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, et al. FK506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK506 in vitro. J Antibiot (Tokyo). 1987;40:1256-1265.
11. Hamajima E, Sugiyama S, Hoshino H, Goto H, Tsukamoto Y, Ozawa T. Effects of FK506, an immunosuppressive agent, on genesis of water-immersion stress-induced gastric lesions in rats. Dig Dis Sci. 1994;39:713-720.
12. Matsumoto T, Iida M, Nakamura S, Hizawa K, Kuroki F, Fujishima M. Preventive effect f immunosuppressive agent against indomethacin-induced small intestinal ulcers in rats. Dig Dis Sci. 1994;39:787-795.
13. Gewirtz AT, Sitaraman SV. Tacrolimus Fujisawa. Curr Opin Investig Drug. 2002;3:1307-1311.
14. Kaibori M, Sakitani K, Oda M, Kamiyama Y, Masu Y, Nishizawa M, et al. Immunosuppressant FK506 inhibits inducible nitric oxide synthase gene expression at a step of NF-κB activation in rat hepatocytes. J Hepatol. 1999;30:1138-1145.
15. Attur MG, Patel R, Thakker G, Vyas P, Levartovsky D, Patel P, et al. Differential anti-inflammatory effects of immunosuppressive drugs: cyclosporin, rapamycin and FK-506 on inducible nitric oxide synthase, nitric oxide, cyclooxygenase-2 and PGE2 production. Inflamm Res. 2000;49:20-26.
16. Nunokawa Y, Oikawa S, Tanaka S. Human inducible nitric oxide synthase gene is transcriptionally regulated by nuclear factor-κB dependent mechanism. Biochem Biopys Res Commun. 1996;223:347-352.
17. Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation. Estimation of neutrophil content with an enzyme marker. J invest Dermatol. 1982;78:206-220.
18. Ohkawa H, Ohnishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95:351-358.
19. Somogyi A, Kovacs K, Selye H. Jejunal ulcers produced by indomethacin. J Pharm Pharmacol. 1969;21:122-123.
20. Bjarnason I, Zanelli G, Smith T, Prouse OP, Williams P, Smethurst P, et al. Nonsteroidal anti-inflammatory drug-induced intestinal inflammation in humans. Gastroenterology. 1987;93:480-489.
21. Rodfern JS, Blair AJ, Lee E, Feldman M. Gastrointestinal ulcer formation in rabbits immunized with prostaglandin E2. Gastroenterology. 1987;93:744-752.
22. Boughton-Smith N, Evans SM, Laszlo F, Whittle BJR, Moncada S. The induction of nitric oxide synthase and intestinal vascular permeability by endotoxin in the rat. Br J Pharmacol. 1993;110:1189-1195.
23. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radicals production by peroxyl radical production by peroxynitrite: implication for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A. 1990;87:1620-1624.
24. Miller MJ, Thompson JH, Zhang XJ, Sadowska-Krowicka H, Kakkis JL, Munshi UK, et al. Role of inducible nitric oxide synthase expression and peroxynitrite formation in guinea pig ileitis. Gastroenterology. 1995;109:1475-1483.
25. Yasuhiro T, Ukawa H, Kato S, Takeuchi K. Involvement of nitric oxide (NO) and inducible NO synthase in the pathogenesis of inflammatory gastric lesions induced by compound 48/80 in rats. J Physiol (Paris). 1997;91:131-138.
26. Yasuhiro T, Korolkiewicz RP, Kato S, Takeuchi K. Role of nitric oxide in pathogenesis of serotonin-induced gastric lesions in rats. Pharmacol Res. 1997;36:333-338.
27. Bertrand V, Guimbaud AP, Tulliez M, Mauprivez C, Sogni P, Couturier D, et al. Increase in tumor necrosis factor-α production linked to the toxicity of indomethacin for the rat small intestine. Br J Pharmacol. 1998;124:1385-1394.
28. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide; physiology, pathophysiology and pharmacology. Pharmacol Rev. 1991;43:109-142.
29. Santucci L, Fiorucci S, Di Matteo FM. Role of tumor necrosis factor-α release and leukocyte margination in indomethacin-induced gastric injury in rats. Gastroenterology. 1995;108:393-401.
30. Ho S, Clipstone N, Timmermann L, Northrop J, Graef I, Fiorentino D, et al. The mechanism of action of cyclosporine A and FK506. Clin Immunol Immunopathol. 1996;80:S40-S45.
31. Baeuerle PA, Henkel T. Function and activation of NF-kappaB in the immune system. Annu Rev Immunol. 1994;12:141-179.